OAB drugs draw flak for allegedly weak efficacy
April 11 2012
An FDA advisory panel endorsed Astellas' overactive bladder medication mirabegron April 6, but not everyone is on board.
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.